# GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

> **NCT02639130** · PHASE4 · COMPLETED · sponsor: **Diabeteszentrum Bad Lauterberg im Harz** · enrollment: 67 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Exendin [9-39]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02639130
- **Lead sponsor:** Diabeteszentrum Bad Lauterberg im Harz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639130, "GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02639130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*